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Blurring the boundary between innate and adaptive immune system, natural killer (NK) 
cells, a key component of the innate immunity, are recognized as potent anticancer 
mediators. Extensive studies have been detailed on how NK cells get activated and 
recognize cancer cells. In contrast, few studies have been focused on how tumor micro-
environment-mediated immunosubversion and immunoselection of tumor-resistant 
variants may impair NK cell function. Accumulating evidences indicate that several cell 
subsets (macrophages, myeloid-derived suppressive cells, T regulatory cells, dendritic 
cells, cancer-associated fibroblasts, and tumor cells), their secreted factors, as well as 
metabolic components (i.e., hypoxia) have immunosuppressive roles in the tumor micro-
environment and are able to condition NK cells to become anergic. In this review, we will 
describe how NK cells react with different stromal cells in the tumor microenvironment. 
This will be followed by a discussion on the role of hypoxic stress in the regulation of 
NK cell functions. The aim of this review is to provide a better understanding of how 
the tumor microenvironment impairs NK cell functions, thereby limiting the use of NK 
cell-based therapy, and we will attempt to suggest more efficient tools to establish a 
more favorable tumor microenvironment to boost NK cell cytotoxicity and control tumor 
progression.
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introduction
Natural killer (NK) cells are lymphoid cells that are considered to be major innate effector cells. They 
are endowed with a natural ability to kill tumor cells and infected cells (1). NK cell lytic functions 
are regulated by a balance of activating and inhibiting signals originating from membrane receptors 
(1). Despite their effective antitumor activity, their contribution in controlling solid tumor progres-
sion remains elusive. The immunosuppressive tumor microenvironment is undoubtedly involved in 
tumor evasion from NK cell-mediated killing through several cellular and metabolic factors. Immune 
and stromal cells as well as the hypoxic stress inside the tumor microenvironment are known to 
be negative regulators of NK cell infiltration into solid tumors and cytotoxicity (1). Tumor cells 
themselves develop several strategies to evade NK cell-mediated killing. In this regard, hypoxic stress 
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through its ability to induce tumor resistance and to regulate the 
differentiation and function of immune-suppressive cells plays a 
determinant role in shaping the NK cell phenotype and function.
In this review, we propose an insight on how tumor microen-
vironment inhibits NK cell functions and how this may impact 
the therapeutic use of NK cells in anticancer treatments.
Cell-Mediated immune Suppression 
Toward NK Cells in the Tumor 
Microenvironment
The tumor microenvironment is a complex network of tumor 
cells, immune cells, stromal cells, and extracellular matrix 
accomplishing proliferation, migration, and dissemination of 
tumor cells. The immune cell subset comprises CD8+ T cells, 
CD4+ T cells, NK cells, and myeloid cells [dendritic cells (DCs), 
M2-macrophages, myeloid-derived suppressor cells (MDSCs)]. 
Despite the recognized role of NK cells in clearing circulating 
tumor cells (leukemia cells, metastatic cells) (2–4), the antitumor 
functions of NK cells in solid tumors are frequently mentioned 
due to the more favorable prognosis associated with higher NK 
cell infiltration in some type of cancers (5), the inverse correlation 
between natural cytotoxic activity and cancer incidence (6), or 
the faster tumor growth in NK cell-depleted mouse models (7–9).
Natural killer cells enter solid tumor site by extravasations 
through tumor vasculature (10). CXCR3 is a major chemokine 
receptor involved in NK cell migration toward tumor following a 
gradient of the tumor-derived chemokine (C-X-C motif) ligands 
CXCL9, 10, and 11 (11, 12). In particular, increased CXCL10 
expression in melanoma tumors results in increased infiltration 
of adoptively transferred CXCR3-positive expanded NK cells, 
reflecting the role of CXCL10-induced chemoattraction (12). 
However, infiltrated NK cells often display a suppressed pheno-
type inside solid tumors. Accumulating evidence indicates that 
tumor-residing cells as well as a series of microenvironmental 
factors are endowed with suppressive properties that affect NK 
cell reactivity and inhibit their functions (Figure 1).
Macrophage Polarization Regulates  
NK Cell-Mediated Cytotoxicity
Within the tumoral tissue, macrophages and other myeloid cells 
constitute a major component of the immune infiltrate (13, 14). 
They differentiate into tumor-associated macrophages (TAM) 
with expression of TAM markers such as CD206 (15). Exposure 
of TAM to tumor-derived cytokines such as IL-4, IL-10, IL-13, 
and M-CSF is able to convert them into polarized type II or 
M2 macrophages with immune-suppressive activities resulting 
in tumor progression (15). M2-polarized macrophages appear 
to contribute to immune suppression through the production 
of immunosuppressive factors such as IL-10 and TGF-β (16). 
Recently, the role of myeloid cells including macrophages in 
immunosuppression of NK cells has been better understood by 
the involvement of A2AR receptors (17). Myeloid-selective dele-
tion of A2ARs significantly activates macrophages by favoring 
M1 polarization, reduces lung metastasis, and increases CD44 
expression on tumor-associated NK cells and T cells as well as 
numbers and activation of NK cells and antigen-specific CD8+ 
T cells in lung infiltrates (17). In a xenografted lung carcinoma 
model, increased expression of surfactant protein-A (SP-A) 
was reported to be associated with reduced tumor growth and 
increased M1-TAM and NK cell recruitment and activation at 
the tumor site (18).
Myeloid-Derived Suppressor Cells Suppress NK 
Cell Activity
Myeloid-derived suppressor cells represent additional myeloid 
subsets involved in tumor-induced immunosuppression (19). 
MDSCs comprise immature macrophages, granulocytes, and 
DCs. Their expansion and immunosuppressive functions are 
well documented in tumor-bearing mice and cancer patients. As 
such, the NK cell activity was found to be inversely correlated 
with MDSC expansion (20, 21). In addition, MDSC-mediated 
inhibition of NK cells was found to be cell contact dependent 
via membrane-bound transforming growth factor-β (TGF-β) on 
MDSC (21) or inhibition of perforin and signal transducer and 
activator of transcription 5 (Stat5) activity in NK cells (20). MDSC 
from patients with hepatocarcinoma also show inhibitory effects 
on autologous NK cells after coculture (22). This inhibition was 
also found to be cell contact dependent and to involve blocking 
of the activating receptor NKp30 on NK cells (22).
CD4+CD25+ T Regulatory Cells inhibit NK Cell 
Cytolytic Functions
T regulatory cells (Treg) are well described for their immunosup-
pressive functions (23). Studies performed by Trzonkowski et al. 
(24) and Xu et al. (25) report direct inhibitory effects of Treg on 
NK cell cytolytic functions and expression of the CD69 activa-
tion marker following in vitro cocultures. These studies indicate 
that the production of TGF-β by Treg is at least one mechanism 
of Treg-mediated NK cell inhibition. In  vivo, Treg depletion 
was shown to increase NK cell proliferation by a mechanism 
involving IL-15Rα expression on DCs (26). In a murine model, 
such depletion was also shown to favor NKG2D-mediated tumor 
rejection (27).
Dendritic Cells Modulate NK Cell Cytotoxicity
The incrimination of TGF-β in the modulation of NK cell cyto-
toxicity is also reported when NK cells are cocultured with DCs. 
Signal transducer and activator of transcription 3 (STAT3) phos-
phorylation in DCs was reported to be associated with increased 
secretion of TGF-β, which inhibited NK cell activity, and inhibi-
tion of TGF-β restored NK cell functions (28). TGF-β production 
by DCs can be induced by coculture of immature DC with lung 
carcinoma cells (29) or by stimulation with LPS (30). Secretion 
of IL-6 and IL-10 by DC has also been incriminated in dendritic 
cell-mediated NK cell inhibition (31). Nevertheless, some reports 
show that DC can also activate NK cell functions. IL-15-stimulated 
DCs acquire the ability to increase surface expression of the NK 
cell-activating receptors NKp30 and NKp46, which is associated 
with an increased tumor target killing (32). This activation is cell 
contact dependent and required membrane-bound IL-15 on DC. 
DCs were also reported to induce NK cell proliferation and to 
activate NKp30 receptor-signaling in NK cells (33).
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Cancer-Associated Fibroblasts Decrease NK 
Cell-Mediated Cytotoxicity
Among the stromal cells, modified/activated fibroblasts, often 
termed cancer-associated fibroblasts (CAFs), are considered 
to play a central role in the complex process of tumor–stroma 
interaction. CAFs, the prominent stromal cell population in most 
types of human carcinomas, are α-SMA (alpha-smooth muscle 
actin) positive, spindle-shaped cells, which closely resemble 
normal myofibroblasts but express specific markers [i.e., FAP 
(fibroblast-associated protein), FSP-1 (fibroblast specific protein 
1), and PDGFR-β (platelet-derived growth factor)] together with 
vimentin (a mesenchymal marker) and the absence of epithelial 
(cytokeratin, E-cadherin) and fully differentiated smooth muscle 
(smoothelin) markers (34–36). CAFs differentiate in the tumor 
FiGURe 1 | interactions between NK and stromal cells within the solid tumor microenvironment. Activating and inhibiting interactions of stromal cells with 
NK cells in the tumor microenvironment. : secretion; ▬ : membrane-bound; (+): activation; (−): inhibition.
microenvironment in a TGF-β-dependent manner from other 
cell types such as resident fibroblasts, mesenchymal stem cells, 
and endothelial and epithelial cells (37, 38). In the tumor stroma, 
CAFs produce and secrete several factors such as extracellular 
matrix proteins (i.e., collagen I, III, IV), matrix metalloproteinases 
(MMPs), proteoglycans (i.e., laminin, fibronectin), chemokines 
(i.e., CXCL1, CXCL2, CXCL8, CXCL6, CXCL12/SDF1, CCL2, 
and CCL5), vascularization promoting factors (i.e., PDGF and 
VEGF), and other proteins that affect tumor cells’ proliferation, 
invasiveness, and survival (i.e., TGF-β, EGF, HGF, and FGF) 
(39). Consequently, CAFs have been involved in tumor growth, 
angiogenesis, tissue invasion, and metastasis (40).
During the past few years, these activated tumor-associated 
fibroblasts have also been involved in the modulation of the 
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antitumor immune response, especially by the secretion of solu-
ble immunosuppressive factors in the tumor microenvironment 
(TGF-β, IL-1β, IL-6, and IL-10) (41). As such, CAFs can poten-
tially affect both innate and adaptive antitumor immune response 
by increasing the recruitment to tumor of myeloid-derived 
suppressive cells (MDSC), by decreasing antigen presentation, 
by increasing the numbers of Tregs, by decreasing T-cell prolif-
eration, cytotoxic T-cell (CTL) function and maturation, or by 
inhibiting B cell activation and differentiation (41, 42). Different 
studies also involved CAFs in the modulation of the NK cell func-
tionality. Indeed, the secretion of TGF-β by CAFs could attenuate 
the expression of NK cell-activating receptors including NKG2D, 
NKp30, and NKp44 (43, 44). More recently, studies involving 
melanoma and hepatocellular and colorectal carcinoma-derived 
fibroblasts have shown that CAFs can decrease NKG2D expres-
sion on NK cells surface through the secretion of prostaglandin 
E2 (PGE2) and/or indoleamine-2,3-dioxygenase (IDO). In 
parallel, perforin and granzyme B expression (involved in NK 
cell-mediated killing of target cells) also seem to be decreased 
by coculture of NK cells with CAFs, affecting their lytic potential 
(45–47). Altogether, these findings highlight the direct and indi-
rect action of CAFs on various levels of the antitumor immune 
response and on NK cells antitumor activity within the tumor 
microenvironment.
Tumor Cells May Develop Strategies to evade 
NK Cell-Mediated Lysis
In many cancers, tumor cells down-regulate surface expression 
of MHC-I molecules in order to evade CD8-dependent T-cell 
killing, making them more susceptible to NK cell-dependent 
killing. Cancer cells can also up-regulate NKG2D ligands fol-
lowing activation of NFκB or Sp transcription factors (48). 
However, tumor cells also develop various strategies to inhibit 
NK cell-mediated cytotoxicity. Indeed, NK cells from multiple 
myeloma patients were shown to constitutively express the 
inhibitory receptor PD-1, as compared to NK cells from healthy 
donors, which contributes to NK cell inhibition by multiple 
myeloma cells (49). When the authors inhibit the PD-1/PD-L1 
axis using lenalidomide or a blocking antibody, they restored 
NK cell lytic functions against tumor cells. In addition, tumor 
cells secrete a number of immunosuppressive cytokines such as 
TGF-β. In this regard, neuroblastoma cell-derived TGF-β has 
been reported to down-regulate the activating receptor NKp30 
(50). Melanoma cells are also able to inhibit the expression of 
activating NK cell receptors including NKp30, NKp44, and 
NKG2D, resulting in impairment of NK cell-mediated cytotox-
icity (51). This inhibitory effect is mediated via the production 
of IDO and PGE2 by melanoma cells. Tumor cells may release 
soluble NKG2D ligands through proteolytic cleavage, resulting 
in down-regulation of NKG2D and impairment of NK cell lytic 
functions (52, 53). The inhibitory consequences of releasing 
soluble NK cell receptor ligands may not be systematic. Indeed, 
NKp30 activation by tumor-released vesicles containing HLA-B-
associated transcript 3 (BAT3), a ligand for NKp30, was reported 
(54). Very recently, Deng et  al. demonstrated that shedding of 
the NKG2D ligand MULT1 results in NK cell activation and 
increased surface expression of NKG2D (55). As suggested by 
the authors, the differential affinity of MULT1 (high-affinity 
NKG2D ligand) and MICA/B (low-affinity NKG2D ligand) for 
NKG2D may explain this discrepancy. Recently, Nanbakhsh et al. 
reported that the induction of c-myc in leukemic cells resistant 
to cytarabine resulted in up-regulation of NKG2D ligands (56). 
Since deregulated expression of c-myc is associated with many 
cancers in human, it raises the question of the expression of 
NK cell-activating ligands on c-myc-altered solid tumors. We 
and others have also provided evidence indicating a role of HIF 
factors in tumor resistance to NK cell-mediated lysis, which is 
further detailed in Section “Consequences of Hypoxia-Induced 
HIF Stabilization on NK Cell Functions.”
Consequences of Hypoxia-induced HiF 
Stabilization on NK Cell Functions
Microenvironmental hypoxia is a prominent feature of solid 
tumors and is involved in fostering the neoplastic process and in 
the modulation of immune reactivity (57). It results from inad-
equacies between the tumor microcirculation and the oxygen 
demands of the growing tumor mass, which leads to a lowering of 
oxygen partial pressure and a metabolic switch toward glycolysis 
(58). Tumor hypoxia is a negative prognostic and predictive factor 
due to many effects on the selection of hypoxia-surviving clones 
(59), activation of the expression of genes involved in apoptosis 
inhibition (60), angiogenesis (61), invasiveness and metastasis 
(62), epithelial-to-mesenchymal transition (63), and loss of 
genomic stability (64). Accumulating evidences indicate that 
tumor hypoxia is also involved in the loss of immune reactivity 
either by decreasing tumor cell sensitivity to cytotoxic effectors or 
by promoting immunosuppressive mechanisms (57).
Cellular Adaptation to Hypoxia Through 
Hypoxia-inducible Factors
Cells adapt to hypoxic microenvironment by regulation of 
hypoxia-inducible family of transcription factors (HIFs). This 
family comprises three members: HIF-1, HIF-2, and HIF-3. HIF-1 
is a heterodimeric protein composed of a constitutively expressed 
β-subunit and an O2-regulated α-subunit. In the presence of 
O2, HIF-1α is hydroxylated on proline residue 402 and/or 564 
by prolylhydroxylase domain protein 2 (PHD2), resulting in its 
interaction with the von Hippel-Lindau (VHL) tumor suppressor 
protein, which recruits an E3 ubiquitin-protein ligase that even-
tually catalyzes poly-ubiquitination of HIF-1α, thereby targeting 
it for proteasomal degradation (1). Under hypoxic conditions, 
hydroxylation is inhibited and HIF-1α rapidly accumulates, 
dimerizes with HIF-β, binds to the core DNA-binding sequence 
50-RCGTG-30 [R being a purine base (adenine or guanine)] in the 
promoter region of target genes, recruits coactivators, and activates 
transcription (65). In addition, oxygen-dependent hydroxylation 
of asparagine-803 by factor inhibiting HIF-1 (FIH-1) blocks the 
interaction of HIF-1α with the coactivators P300/CBP under nor-
moxic conditions, resulting in suppression of HIF transcriptional 
activity (66–68). Similar to HIF-1α, HIF-2α is also regulated by 
oxygen-dependent hydroxylation. HIF-1α and HIF-2α are struc-
turally similar in their DNA-binding regions and dimerization 
domains but differ in their transactivation domains. Consistently, 
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they share many target genes, but each one also regulates a unique 
set of genes (69). HIF-3α lacks the transactivation domain and 
may function as an inhibitor of HIF-1α and HIF-2α (70).
Hypoxic and Pseudo-Hypoxic Tumor Cells Are 
Resistant to NK Cell-Mediated Killing
It is now well established that the hypoxic tumor microenviron-
ment favors the emergence of tumor variants with increased 
metastatic and invasive potential and alters immune reactivity 
as well (57).
Fink and colleagues reported the inhibition of NK cell cyto-
toxicity toward liver tumor cell lines under hypoxic conditions, 
suggesting for the first time that hypoxia is able to confer tumor 
resistance to NK cell-mediated cytotoxicity (71). Another study 
demonstrated that hypoxia decreased the expression of MICA (a 
NKG2D ligand) on osteosarcoma cell surface with a consistent 
decrease in the susceptibility of these cells to NK cell-mediated 
cytotoxicity (72). Consistently, HIF-1α knockdown using small 
interfering RNA increased the expression of cell surface MICA and 
concomitantly increased the level of soluble MICA. HIF-1α was 
also found to be inversely correlated with MIC gene expression, 
indicating that hypoxia was involved in the inhibition of NK cell 
reactivity toward tumor cells. Recently, we showed that hypoxia-
induced autophagy in tumor cells mediated resistance to CTL (73). 
In this context, Baginska et al. demonstrated that hypoxia-induced 
autophagy in tumor cells was also involved in tumor resistance 
to NK cells via granzyme B degradation in autophagosomes (74).
In the particular context of renal cancer, hypoxic signaling 
is frequently constitutively active owing to the majority of renal 
cancers presenting with clear cell carcinoma (ccRCC) histology 
(75), which is usually associated with mutational or functional 
inactivation of the VHL gene (76). The VHL pathway targets the 
hypoxia-inducible factors (HIFs) family of transcription factors, 
in particular HIF-1α and HIF-2α, for ubiquitin-mediated degra-
dation via the proteasome (77). Consequently, VHL inactivation 
leads to constitutive stabilization of HIFs, a process known as 
pseudo-hypoxia, and increased expression of HIF target genes. 
Our group has recently shown that, in VHL-mutated ccRCC 
cells, HIF-2 stabilization caused by mutated VHL induces up-
regulation of ITPR1 which is involved in ccRCC resistance to NK 
cells (78). NK cells were found to induce a contact-dependent 
autophagy in ccRCC cells that was dependent on ITPR1 expres-
sion in tumor cells. Blocking ITPR1 expression in ccRCC cells 
inhibited NK cell-induced autophagy and suppressed ccRCC 
resistance to NK cells.
On the contrary, in non-tumoral cells, Luo and colleagues 
demonstrated that HIF-1α overexpression in HK-2 cells 
induces MICA expression and enhances NK cell cytotoxicity 
toward target cells as well as IFNγ secretion by NK cells (79). 
Antibody blocking experiments using anti-MICA mAb were 
able to down-regulate NK cell-mediated killing and IFNγ secre-
tion toward HIF-1α-overexpressing HK-2 cells confirming the 
involvement of MICA in the increased NK cell reactivity.
Hypoxia inhibits NK Cell Functions via HiFs
The specific role of hypoxia and HIFs on NK cells is not well 
studied.
Balsamo and colleagues showed that NK cells adapt to a 
hypoxic environment by up-regulating HIF-1α. They demon-
strated that, under hypoxia, NK cells lose their ability to up-
regulate the surface expression of the major activating NK-cell 
receptors (NKp46, NKp30, NKp44, and NKG2D) in response to 
IL-2 or other activating cytokines (including IL-15, IL-12, and 
IL-21). These altered phenotypic features correlated with reduced 
responses to activating signals, resulting in impaired capability of 
killing infected or tumor target cells. However, hypoxia does not 
significantly alter the surface density and the triggering function 
of the Fc-γ receptor CD16, thus allowing NK cells to maintain 
their capability of killing target cells via antibody-dependent 
cellular cytotoxicity (80).
Hypoxic primary tumors were shown to provide cytokines 
and growth factors capable of creating a pre-metastatic niche 
and a reduction of the cytotoxic functions of NK cells. In fact, 
Sceneay et al. reported that injection of mice with hypoxic mam-
mary tumor cells resulted in increased CD11b+/Ly6Cmed/Ly6G+ 
myeloid and CD3−/NK1.1+ immune cell lineages infiltration 
into the lung and led to increased metastatic burden in mam-
mary and melanoma experimental metastasis models (81). The 
cytotoxicity of NK cells was significantly decreased, resulting in 
a reduced antitumor response that allowed metastasis formation 
in secondary organs to an extent similar to that observed fol-
lowing depletion of NK cells. Sarkar and colleagues confirmed 
that hypoxia reduced NK cell killing of multiple myeloma cell 
lines (82). They showed that hypoxia significantly decreased 
expression of the activating receptor NKG2D by NK cells and of 
intracellular granzyme B and perforin. Whether HIF factors were 
able to directly regulate the expression of granzymes genes is not 
documented, but perforin has been reported not to be a direct 
target gene of HIF-1 (83).
Despite detailed description of the detrimental effects 
of hypoxia on NK-cell responses, the underlying molecular 
mechanisms remain unclear. In particular, whether HIF or other 
hypoxia-related factors are able to directly control NK cell recep-
tor expression remain to be clarified.
indirect Consequences of Hypoxic Stress on  
NK Cell Cytotoxic Functions
Despite the direct consequences of hypoxic stress on NK cells, 
intratumoral hypoxia is also involved in increased tumor infiltra-
tion by Treg and MDSC and in M2-polarization (57), which are 
cellular subsets that negatively regulate NK cell lytic functions 
(see Cell-Mediated Immune Suppression Toward NK Cells in 
the Tumor Microenvironment). Hypoxic stress is also involved 
in increased expression and secretion by tumor cells of NK 
cell-inhibiting cytokines such as TGF-β (84, 85). Of note, NK 
cell adhesion on hypoxic endothelial cells was reported to be not 
altered (86), but NK cell infiltration into hypoxic tumors has not 
been extensively studied.
NK Cell: A Role in Tumor immunoediting
The major focus of immunotherapy approaches has been enhanc-
ing the effectiveness of host antitumor immunity. However, while 
accumulating evidences indicate that tumor microenvironment 
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might evade the innate host immune response to ensure tumor 
development and survival (58, 87), NK cells have also been 
reported to play a role in the selection of tumor-resistant and 
tumor-tolerant cells and therefore to shape tumor microenvi-
ronment (88). While the mechanisms of CTL-induced tumor 
editing are well known (89), only limited knowledge on how 
NK cells induce tumor editing is available. In this regard, the 
involvement of NK cells in immune editing has been studied in 
relation to NKG2D and DNAM1 (90, 91). Guillerey and Smyth 
have elegantly demonstrated the NK cell activity in the cancer 
immune editing process with particular emphasis on the elimi-
nation and escape phases (92). NK cells have been also shown to 
kill immature DC because of their low amount of surface human 
leukocyte antigen (HLA) class I molecules (33) and therefore 
impact the quality of adaptive immune response. In this regard, 
Ghadially et al. have reported data indicating that in the absence 
of NKp46, graft-versus-host disease (GVHD) is greatly exacer-
bated, resulting in rapid mortality of the transplanted animals 
(93). Furthermore, these authors have demonstrated that the 
exacerbated GVHD is the result of an altered ability of immune 
cells to respond to stimulation by immature DCs (94). Buchser 
et al. have shown that classic cytolytic cells, including NK cells, 
can often promote survival and autophagy in target cells (95). 
These authors provided evidence indicating that NK cells are 
a primary mediator of autophagy in tumor target cells by a 
mechanism involving cytokines (IL-10, IL-2, IFNγ) and that 
cell-to-cell contact strongly enhanced lymphocyte-mediated 
autophagy. The authors suggested that the NK cell-mediated 
autophagy promotes cancer cell survival and may represent an 
important target for development of novel therapies.
NK Cell-Based immunotherapies in the 
Context of Tumor Microenvironment 
Complexity and Heterogeneity
Natural killer cell-based immunotherapies have the advantage 
of circumventing antigen recognition restriction since NK cells 
do not need antigen recognition to kill tumor targets. In this 
context, NK cell infusion has been useful in leukemic patients, 
probably due to their primary location being the blood. Indeed, 
most of hematological malignancies display an autologous NK 
cell deficiency specifically in myeloid diseases. Autologous NK 
cells do not control acute myeloid leukemia (AML) blasts and 
several mechanisms have been hypothesized: down-regulation 
of the ligands for NK-cell activating receptors or up-regulation 
of NK cell inhibitory receptors (96). Allogeneic NK cells do not 
bear this deficiency and have demonstrated their ability to kill 
AML blasts targets. In this context, the killer Ig-like receptor 
(KIR)-ligand mismatch is considered fundamental for their anti-
tumor effects (97, 98, 99). Modulating the immune reconstitution 
following allogeneic transplantation with NK cells is a potential 
powerful tool to increase the graft versus leukemia (GvL) effect 
against AML blasts and tumor cells (100). NK cells do recover 
early following allogeneic transplantation and exert cytotoxicity 
through MHC unrestricted killing. High numbers of allogeneic 
circulating NK cells improved remission duration in patients with 
leukemia and consolidate engraftment following haploidentical 
transplants (101).
On the other hand, the therapeutic potential of NK cells 
in solid tumors is not yet clearly established. However, pre-
clinical studies support the antitumor activity of NK cells 
against solid tumors (102). Phase I and phase II clinical trials 
based on adoptive transfer of irradiated NK cell lines or allo-
geneic NK cells have been made in breast, ovarian, melanoma, 
and renal cancer patients (98, 103). These trials revealed mild 
and transient toxicities following NK-92 infusion and some 
severe syndromes following allogeneic NK cell administration. 
Further studies are still needed to increase NK cell persistence 
and expansion.
Moreover, producing sufficient amounts of allogeneic NK 
cells for clinical applications remain a technical challenge in 
cell therapy programs despite their useful and safe infusion 
10 years ago (104). Dampening negative regulators of NK cell 
lytic functions should also be explored, in particular in the 
context of solid tumors. Strategies aimed at inhibiting NK cell 
suppressors such as TGF-β, expansion of immunosuppressive 
cells, and expression of inhibitory checkpoints should be con-
sidered. In particular, targeting HIF-1α by antisense plasmid 
in xenografted mice led to NK cell-dependent tumor rejection 
(105). Various anticancer drugs have been shown to inhibit 
HIFs (106, 107). We believe that pharmacologic manipula-
tion of hypoxic signaling will result in increased target killing 
by effector cells and in general improving of antitumoral 
immunotherapy. Whether the suppression of hypoxia may be 
a promising strategy that is selective for facilitating immuno-
therapeutic efficacy in cancer patients is at present investigated. 
Nevertheless, a better understanding of functionally distinct 
KIR or NK cell receptor subsets within NK cell population is 
still needed for designing optimal immunotherapy based on 
NK cell administration or reactivation.
Conclusion
During the last few years, cancer immunotherapy has emerged 
as a safe and effective alternative to cancers that do not respond 
to classical treatments including those types with high aggres-
siveness. New immune modulators like cytokines, blockers of 
CTLA4/CD28 and PD-1/PD-L1 interactions, or adoptive cell 
therapy have been developed and approved to treat solid tumors 
and hematological malignant diseases. In these scenarios, cyto-
toxic lymphocytes mainly CTLs and NK cells are the ultimate 
responsible for killing the cancer cells and eradicating the tumor. 
Many mechanisms have been proposed for the functional 
inactivation of tumor-associated NK cells. Thus, the definition 
of tumor microenvironment-related immunosuppressive factors, 
along with the identification of new classes of tissue-residing NK 
cell-like innate lymphoid cells, represents key issues to design 
effective NK-cell-based therapies for solid tumors.
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